Fueling Research, Feeding Discovery

New Products

Comprehensive assay kits for drug screening

  • Kit Solutions

    Kit Solutions

    AntBio offers mIHC kits, organoid culture kits, conventional and One-step ELISA assay kits, RNA/DNA/protein interaction kits, etc.

  • Cytokine Solutions

    Cytokine Solutions

    AntBio provides related cytokines of different cell types (organoids, stem cells, immune cells, etc.) with high purity and high activity verification

  • Target Protein Solutions

    Target Protein Solutions

    AntBio offers high performance target proteins in different research areas (antibody drugs, ADC drugs, CAR-T, small molecule drugs, etc.)

  • Loading Control

    Loading Control

    AntBio offers reliable and high-quality loading control antibodies, essential for accurate normalization in Western blotting and other protein quantification assays.

Featured Products

Memento Doll with Every Order

Anniversary activity

Sep 1 - Oct 31

20% off for 5+ items

Enjoy 20% discount on 5 or more items storewide including OneStep ELISA Kits, mIHC Kits, IHC antibodies, Organoid Culture Kits, PTMs antibodies and so on.

Promo Period: 1 July 2026 to 31 Dec 2026

View Promotions

New Semester Launch | Spacial Biology

Discount Code: ANT2608@20

Promotion valid from 15 Aug to 31 Oct, 2026

View Promotions
bg

About Us

AntBio - Fueling Research, Feeding Discovery

AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.

About Us

50k

Happy Clients

100k

Products

70+

Doctor/Expert

20,000+

Publications

ARTICLES

Latest News

11 Sep 2026 by AntBio
FGFR2b Receptor‑Tyrosine‑Kinase: Mechanisms and Research Tools for Gastric‑Cancer Target‑Oriented Studies

FGFR2b Receptor‑Tyrosine‑Ki...

This academic article reviews FGFR2b receptor‑tyrosine‑kinase structural features, FGF‑driven downstream signalling cascades, heterogeneous protein‑expression patterns in gastric‑cancer pre‑clinical samples. Researchers explore multiple FGFR2b‑targeted intervention concepts, IHC assay‑standardization considerations, and isoform‑specific...

FGFR2b Receptor‑Tyrosine‑Ki...

This academic article reviews FGFR2b receptor‑tyrosine‑kinase structural features, FGF‑driven downstream signalling cascades, heterogeneous protein‑expression patterns in gastric‑cancer pre‑clinical samples. Researchers...

View Details
B7‑H3 (CD276): Dissecting a Context‑Dual Immune Checkpoint for Tumour‑Immunology Research

B7‑H3 (CD276): Dissecting a Context‑D...

This academic article dissects context‑dependent dual functions of B7‑H3 (CD276) within tumour immunology basic‑research workflows. It covers gene‑protein structural features, divergent immune regulatory outputs, tumour‑related signalling axes, multiple pre‑clinical therapeutic...

B7‑H3 (CD276): Dissecting a Context‑D...

This academic article dissects context‑dependent dual functions of B7‑H3 (CD276) within tumour immunology basic‑research workflows. It covers gene‑protein structural features,...

View Details
Immunogenicity Risks of CAR‑T Constructs: Detection and Mitigation in Cell‑Therapy Basic Research

Immunogenicity Risks of CAR‑T Constru...

This academic overview addresses CAR‑T immunogenicity sources including murine‑derived scFv, hinge‑transmembrane segments and gene‑editing components for cell‑therapy basic research. It contrasts pre‑existing humoral responses versus post‑infusion CAR‑specific cellular immunity, engineering...

Immunogenicity Risks of CAR‑T Constru...

This academic overview addresses CAR‑T immunogenicity sources including murine‑derived scFv, hinge‑transmembrane segments and gene‑editing components for cell‑therapy basic research. It...

View Details
Immune‑Checkpoint Antibodies: Disrupting Inhibitory Signals for Tumour Immunology Basic Research

Immune‑Checkpoint Antibodies: Disrupt...

This academic article reviews core immune‑checkpoint biology covering CTLA‑4 and PD‑1/PD‑L1 inhibitory signalling pathways for immuno‑oncology basic research. It compares distinct mechanistic profiles of major checkpoints, monotherapy and combinatorial blockade...

Immune‑Checkpoint Antibodies: Disrupt...

This academic article reviews core immune‑checkpoint biology covering CTLA‑4 and PD‑1/PD‑L1 inhibitory signalling pathways for immuno‑oncology basic research. It compares...

View Details